<DOC>
	<DOCNO>NCT00076388</DOCNO>
	<brief_summary>The purpose study compare effect ZD1839 docetaxel patient advance non-small cell lung cancer ( NSCLC ) recur progressed receive prior treatment platinum-based chemotherapy .</brief_summary>
	<brief_title>Iressa Versus Docetaxel ( Taxotere )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Measurable ( uni dimensional ) disease RECIST criterion lesion previously irradiate non measurable disease Locally advance metastatic NSCLC , amenable curative surgery radiotherapy Advanced nonsmall cell lung cancer ( NSCLC ) recur progressed receive prior treatment platinumbased chemotherapy WHO performance status ( PS ) 02 Absolute Neutrophil Count ( ANC ) &gt; 1.5 x 109/liter ( L ) platelets &gt; 100 x 109/L Life expectancy least 8 week Prior ZD1839 therapy Prior docetaxel treatment NSCLC Less 14 day since completion prior radiotherapy Less 21 day since prior chemotherapy , immunotherapy biological systemic anticancer therapy Evidence clinically active Interstitial Lung Disease Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Newly diagnose CNS metastasis yet treat surgery and/or radiation . Patients previously diagnose treat CNS metastases spinal cord compression may consider evidence clinically SD ( steroid therapy steroid dose taper ) least 28 day Patients pre exist peripheral neuropathy &gt; = grade 2 ( NCI CTC criterion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
</DOC>